From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Public company
Traded as LSEINDV
Industry pharmaceuticals
Founded 1994
Headquarters Richmond, Virginia
Key people
Howard Pien, Chairman
Shaun Thaxter, CEO
Products Subutex/Subuxone
Revenue $1,093 million (2017)[1]
$193 million (2017)[1]
$58 million (2017)[1]
Number of employees
1,012 (2017)[1]

Indivior is a specialty pharmaceuticals business. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.


The company was established as the Buprenorphine division of Reckitt Benckiser in 1994.[2] In December 2014, Reckitt Benckiser spun off its specialty pharmaceuticals business into a separate company named Indivior.[3] By February 2015 the company was capitalised at £2.3 billion on the London Stock Exchange.[4]


The company's main products are Subutex and its Naloxone-combined preparation Suboxone, both substitution products for opioid addiction.[2] Other products include remedies for cocaine and opioid analgesic overdose and treatment for alcohol dependence: the company claims this to be the largest pipeline of addiction drugs in the world.[5]


  1. ^ a b c d "Annual Report 2017" (PDF). Indivior. Retrieved 26 March 2018.
  2. ^ a b "Indivior faces generic challenge". Investors Chronicle. 2 February 2015. Retrieved 22 March 2015.
  3. ^ "RB complete demerger of Indivior - RB". RB. 23 December 2014. Archived from the original on 29 March 2015. Retrieved 21 March 2015.
  4. ^ "Is Indivior PLC The Perfect Partner For AstraZeneca plc In Your Portfolio?". Retrieved 22 March 2015.
  5. ^ "RB spin-out Indivior says addiction pipeline will deliver". Pharmaphorum. 21 November 2014. Retrieved 22 March 2015.

External links

  • Official site
Retrieved from ""
This content was retrieved from Wikipedia :
This page is based on the copyrighted Wikipedia article "Indivior"; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA